Inhibitors of the Oncogenic PA2G4-MYCN Protein-Protein Interface.
MYCN
PA2G4
WS6
inhibitors
neuroblastoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
17 Mar 2023
17 Mar 2023
Historique:
received:
08
02
2023
revised:
01
03
2023
accepted:
14
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
MYCN is a major oncogenic driver for neuroblastoma tumorigenesis, yet there are no direct MYCN inhibitors. We have previously identified PA2G4 as a direct protein-binding partner of MYCN and drive neuroblastoma tumorigenesis. A small molecule known to bind PA2G4, WS6, significantly decreased tumorigenicity in
Identifiants
pubmed: 36980710
pii: cancers15061822
doi: 10.3390/cancers15061822
pmc: PMC10046377
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Health and Medical Research Council
ID : APP1016699
Organisme : Cancer Institute of New South Wales
ID : 10/TPG/1-13
Organisme : Cancer Council NSW
ID : PG-11-06
Organisme : National Health and Medical Research Council
ID : APP1125171
Organisme : Cancer Council NSW
ID : RG21-08
Organisme : National Health and Medical Research Council
ID : APP1117183
Références
J Pathol. 2009 Dec;219(4):463-72
pubmed: 19768740
Nat Genet. 2017 Sep;49(9):1408-1413
pubmed: 28740262
Cancer Discov. 2018 Feb;8(2):150-163
pubmed: 29358508
Nat Med. 2016 Jul;22(7):744-53
pubmed: 27213815
PLoS One. 2011 Apr 13;6(4):e18064
pubmed: 21533284
JAAPA. 2017 Oct;30(10):30-36
pubmed: 28953021
PLoS Genet. 2011 Jun;7(6):e1002135
pubmed: 21698133
Oncogene. 2021 Apr;40(13):2367-2381
pubmed: 33658627
PLoS One. 2008 Mar 12;3(3):e1798
pubmed: 18335064
Sci Transl Med. 2015 Nov 4;7(312):312ra176
pubmed: 26537256
N Engl J Med. 2010 Jun 10;362(23):2202-11
pubmed: 20558371
Nat Commun. 2021 Mar 25;12(1):1881
pubmed: 33767157
J Med Chem. 2019 Nov 27;62(22):10005-10025
pubmed: 31188592
Nat Rev Urol. 2017 Jan;14(1):38-48
pubmed: 27872477
Cell. 2011 Sep 16;146(6):904-17
pubmed: 21889194
J Biochem. 2012 Jun;151(6):611-20
pubmed: 22451680
J Biomed Biotechnol. 2010;2010:840518
pubmed: 19911078
Cancer Cell. 2013 Jul 8;24(1):75-89
pubmed: 23792191
J Med Chem. 2007 Jan 11;50(1):74-82
pubmed: 17201411
Med Sci (Basel). 2018 May 25;6(2):
pubmed: 29799508
Cancer Res. 2019 Nov 1;79(21):5652-5667
pubmed: 31501192
Nat Genet. 2011 Sep 04;43(10):929-31
pubmed: 21892158
Nat Rev Drug Discov. 2015 Feb;14(2):130-46
pubmed: 25633797
J Chem Inf Model. 2011 Mar 28;51(3):578-96
pubmed: 21323318
Oncogene. 2010 Mar 4;29(9):1249-59
pubmed: 20101214
Blood. 2011 Sep 8;118(10):2656-8
pubmed: 21765025
Anal Biochem. 2012 Feb 15;421(2):794-6
pubmed: 22209736
Cancer Cell. 2015 Feb 9;27(2):223-39
pubmed: 25670080
Sci Rep. 2017 Apr 11;7:46277
pubmed: 28397808
Nat Rev Cancer. 2014 Apr;14(4):248-62
pubmed: 24622521
Bioinformatics. 2012 Jul 1;28(13):1805-6
pubmed: 22543366
Nat Protoc. 2018 Mar;13(3):530-550
pubmed: 29446774
Mol Cancer. 2021 Jan 15;20(1):15
pubmed: 33451333
FEBS Lett. 2007 Sep 18;581(23):4450-4
pubmed: 17765895
Biopolymers. 2003 Jan;68(1):76-90
pubmed: 12579581
RSC Med Chem. 2021 Jul 27;12(10):1731-1749
pubmed: 34778774
J Clin Invest. 2019 Jul 1;129(9):3924-3940
pubmed: 31260412
Nat Rev Drug Discov. 2007 Nov;6(11):881-90
pubmed: 17971784